Nuclear Factor-kappaB P65/relA Silencing Induces Apoptosis and Increases Gemcitabine Effectiveness in a Subset of Pancreatic Cancer Cells

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2008 Dec 18

PMID 19088029

Citations 71

Authors

Xue Pan

Thiruvengadam Arumugam

Tameyoshi Yamamoto

Pavel A Levin

Vijaya Ramachandran

Baoan Ji

Gabriel Lopez-Berestein

Pablo E Vivas-Mejia

Anil K Sood

David J McConkey

Craig D Logsdon

Affiliations

Soon will be listed here.

Abstract

Purpose: Nuclear factor kappaB (NFkappaB) activity may increase survival and protect cancer cells from chemotherapy. Therefore, NFkappaB activity may be prognostic, and inhibition of NFkappaB may be useful for pancreatic cancer therapy. To test these hypotheses, we examined NFkappaB activity and the effects of inhibiting NFkappaB in several pancreatic cancer cell lines with differing sensitivities to gemcitabine.

Experimental Design: The gemcitabine sensitivity of pancreatic cancer cell lines BxPC-3, L3.6pl, CFPAC-1, MPanc-96, PANC-1, and MIA PaCa-2 were determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and fluorescence-activated cell sorting assays. NFkappaB levels were determined by electrophoretic mobility shift assay and reporter assays. The effects of gemcitabine on NFkappaB activity were determined in vitro and in vivo. NFkappaB was inhibited by silencing of the p65/relA subunit using small interfering RNA in vitro and by neutral liposomal delivery of small interfering RNA in vivo, and the effects were evaluated on gemcitabine sensitivity.

Results: The cell lines L3.6pl, BxPC-3, and CFPAC-1 were sensitive, whereas MPanc-96, PANC-1, and MIA PaCa-2 were resistant to gemcitabine. No significant correlation was observed between basal NFkappaB activity and gemcitabine sensitivity. Gemcitabine treatment did not activate NFkappaB either in vitro or in vivo. Silencing of p65/relA induced apoptosis and increased gemcitabine killing of all gemcitabine-sensitive pancreatic cancer cells. No significant effects, however, were observed on gemcitabine-resistant pancreatic cancer cell lines either in vitro or in vivo.

Conclusions: NFkappaB activity did not correlate with sensitivity to gemcitabine. Silencing of p65/relA was effective alone and in combination with gemcitabine in gemcitabine-sensitive but not gemcitabine-resistant pancreatic cancer cells. Thus, NFkappaB may be a useful therapeutic target for a subset of pancreatic cancers.

Citing Articles

Novel bioinformatic approaches show the role of driver genes in the progression of cervical cancer: An in-silico study.

Yari A, Aghbash P, Bayat M, Lahouti S, Jalilzadeh N, Zadeh L Heliyon. 2024; 10(22):e40179.

PMID: 39634417 PMC: 11616557. DOI: 10.1016/j.heliyon.2024.e40179.

Glycogen synthase kinase 3β: the nexus of chemoresistance, invasive capacity, and cancer stemness in pancreatic cancer.

Uehara M, Domoto T, Takenaka S, Takeuchi O, Shimasaki T, Miyashita T Cancer Drug Resist. 2024; 7:4.

PMID: 38318525 PMC: 10838383. DOI: 10.20517/cdr.2023.84.

Iron oxide nanoparticles trigger endoplasmic reticulum damage in steatotic hepatic cells.

Uzhytchak M, Lunova M, Smolkova B, Jirsa M, Dejneka A, Lunov O Nanoscale Adv. 2023; 5(16):4250-4268.

PMID: 37560414 PMC: 10408607. DOI: 10.1039/d3na00071k.

Chemomodulatory Effect of the Marine-Derived Metabolite "Terrein" on the Anticancer Properties of Gemcitabine in Colorectal Cancer Cells.

Abuhijjleh R, Al Saeedy D, Ashmawy N, Gouda A, Elhady S, Al-Abd A Mar Drugs. 2023; 21(5).

PMID: 37233465 PMC: 10221861. DOI: 10.3390/md21050271.

Fucoxanthin Is a Potential Therapeutic Agent for the Treatment of Breast Cancer.

Lau T, Kwan H Mar Drugs. 2022; 20(6).

PMID: 35736173 PMC: 9229252. DOI: 10.3390/md20060370.

References

Li Y, Ellis K, Ali S, El-Rayes B, Nedeljkovic-Kurepa A, Kucuk O . Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line. Pancreas. 2004; 28(4):e90-5. DOI: 10.1097/00006676-200405000-00020. View

Kuhnel F, Zender L, Paul Y, Tietze M, Trautwein C, Manns M . NFkappaB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis. J Biol Chem. 2000; 275(9):6421-7. DOI: 10.1074/jbc.275.9.6421. View

Rayet B, Gelinas C . Aberrant rel/nfkb genes and activity in human cancer. Oncogene. 1999; 18(49):6938-47. DOI: 10.1038/sj.onc.1203221. View

Bai J, Demirjian A, Sui J, Marasco W, Callery M . Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells. Biochem Biophys Res Commun. 2006; 348(4):1245-53. DOI: 10.1016/j.bbrc.2006.07.185. View

Kashatus D, Chen S, Li X, Westwick J, Davis R, Earp H . The p65/RelA subunit of NF-kappaB suppresses the sustained, antiapoptotic activity of Jun kinase induced by tumor necrosis factor. Mol Cell Biol. 2002; 22(23):8175-83. PMC: 134075. DOI: 10.1128/MCB.22.23.8175-8183.2002. View

Sebens S, Arlt A, Schafer H . NF-kappaB as a molecular target in the therapy of pancreatic carcinoma. Recent Results Cancer Res. 2007; 177:151-64. DOI: 10.1007/978-3-540-71279-4_17. View

Bian X, McAllister-Lucas L, Shao F, Schumacher K, Feng Z, Porter A . NF-kappa B activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J Biol Chem. 2001; 276(52):48921-9. DOI: 10.1074/jbc.M108674200. View

Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, Mikuria K, Fujimoto M, Maehara S . Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int J Oncol. 2007; 31(6):1345-50. View

Melisi D, Chiao P . NF-kappa B as a target for cancer therapy. Expert Opin Ther Targets. 2007; 11(2):133-44. DOI: 10.1517/14728222.11.2.133. View

10.

Bold R, Chandra J, McConkey D . Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann Surg Oncol. 1999; 6(3):279-85. DOI: 10.1007/s10434-999-0279-x. View

11.

Qin X, An D, Chen I, Baltimore D . Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U S A. 2003; 100(1):183-8. PMC: 140921. DOI: 10.1073/pnas.232688199. View

12.

Wang W, Abbruzzese J, Evans D, Larry L, Cleary K, Chiao P . The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res. 1999; 5(1):119-27. View

13.

Ouyang H, Mou L, Luk C, Liu N, Karaskova J, Squire J . Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol. 2000; 157(5):1623-31. PMC: 1885733. DOI: 10.1016/S0002-9440(10)64800-6. View

14.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C . Cancer statistics, 2006. CA Cancer J Clin. 2006; 56(2):106-30. DOI: 10.3322/canjclin.56.2.106. View

15.

Arlt A, Vorndamm J, Breitenbroich M, Folsch U, Kalthoff H, Schmidt W . Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene. 2001; 20(7):859-68. DOI: 10.1038/sj.onc.1204168. View

16.

Weichert W, Boehm M, Gekeler V, Bahra M, Langrehr J, Neuhaus P . High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer. 2007; 97(4):523-30. PMC: 2360349. DOI: 10.1038/sj.bjc.6603878. View

17.

Bergman A, Pinedo H, Peters G . Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). Drug Resist Updat. 2002; 5(1):19-33. DOI: 10.1016/s1368-7646(02)00002-x. View

18.

Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, Chiao P . Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res. 2005; 65(19):9064-72. DOI: 10.1158/0008-5472.CAN-05-1330. View

19.

Landen C, Merritt W, Mangala L, Sanguino A, Bucana C, Lu C . Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther. 2006; 5(12):1708-13. DOI: 10.4161/cbt.5.12.3468. View

20.

Liptay S, Weber C, Ludwig L, Wagner M, Adler G, Schmid R . Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. Int J Cancer. 2003; 105(6):735-46. DOI: 10.1002/ijc.11081. View